Corient Private Wealth’s Standard BioTools LAB Stock Holding History

Corient Private Wealth’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12K	Sell	13,046 -12,954	-50%	-$15.7K	﹤0.01%	2799
2025 Q4	$33.3K	Buy	26,000 +12,980	+100%	+$17.4K	﹤0.01%	2694
2025 Q3	$16.9K	Sell	13,020 -4,980	-28%	-$6.52K	﹤0.01%	2535
2025 Q2	$21.6K	Buy	18,000 +5,000	+38%	+$5.54K	﹤0.01%	2408
2025 Q1	$14K	Hold	13,000	–	–	﹤0.01%	2259
2024 Q4	$22.8K	Hold	13,000	–	–	﹤0.01%	2309
2024 Q3	$25.1K	Buy	13,000 +3,000	+30%	+$5.88K	﹤0.01%	2426
2024 Q2	$17.7K	Buy	+10,000	New	+$24.4K	﹤0.01%	2298

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Corient Private Wealth's LAB Position: Q1 2026 in Review

Corient Private Wealth reduced its Standard BioTools (LAB) stake by 50% in Q1 2026, selling an estimated $15.7K and leaving 13,046 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #2799.

Corient Private Wealth first reported a position in LAB in Q2 2024 and has held it in 8 quarters since. The position peaked at $33.3K in Q4 2025. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

Corient Private Wealth held 13,046 shares of Standard BioTools worth $12K as of Q1 2026.
Corient Private Wealth sold 12,954 Standard BioTools shares in Q1 2026, an estimated $15.7K.
Standard BioTools made up ﹤0.01% of Corient Private Wealth's portfolio in Q1 2026, its #2799 holding.
Corient Private Wealth first reported a position in Standard BioTools in Q2 2024 and has held it in 8 quarters since.
Corient Private Wealth's Standard BioTools position peaked at $33.3K in Q4 2025.
155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.